Jaguar Health JV Reports Positive Preclinical Data for Coca Extract in Post-GLP-1 Weight Management
JAGX is trading near its 52-week low of $2.25 (10% above the low) on elevated volume (4.4× avg).
Summary
Magdalena Biosciences, a joint venture involving Jaguar Health, announced positive preclinical study results for a novel coca leaf extract. The extract prevented weight gain in mice on a high-fat diet without affecting food intake or activity. This candidate is being developed for post-GLP-1 weight loss management, addressing a significant unmet need. This early-stage pipeline development from the joint venture could provide a future growth opportunity for Jaguar Health, following its recent Q1 2026 financial turnaround.
At the time of this announcement, JAGX was trading at $2.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $2.25 to $121.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.